IXICO plc Appointment of Chief Financial Officer (3017P)
February 07 2019 - 2:00AM
UK Regulatory
TIDMIXI
RNS Number : 3017P
IXICO plc
07 February 2019
7th February 2019
IXICO plc
("IXICO" or the "Company")
Appointment of Chief Financial Officer
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, is pleased to announce the appointment of
Grant Nash as the Company's Chief Financial Officer. Grant will
join the Company on 29(th) April 2019 and it is anticipated that he
will join the board in due course.
Grant joins IXICO from the UK Biobank, a national and
international health research data resource, where he has been
Finance Director since 2014. Whilst with the UK Biobank, Grant was
also responsible for the UK Biocentre, which provides biomedical
sample processing and archiving logistics to large-scale research
studies. He was involved in separate fundraisings to raise more
than GBP140 million for a variety of research and development
projects. Prior to his time with the UK Biobank, Grant spent 10
years with Evotec AG, latterly as Senior Vice President of Finance,
where he was responsible for the finance, IT, procurement
facilities and logistics functions. Evotec AG is a drug discovery
business which reached 600 employees and sales of approximately
EUR100 million during his tenure. Grant qualified as a Chartered
Accountant with PwC.
Conor Woolfson who assumed the role of interim Head of Finance
in December 2018, will continue to perform these duties prior to
Grant's appointment, at which time he will then continue in his
role of Group Financial Controller, reporting to Grant.
Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted
to welcome Grant to the Company and I look forward to him bringing
his financial leadership skills and experience in the sector to
IXICO. I would also like to thank Conor Woolfson, who in addition
to his responsibilities as Group Financial Controller, stepped into
the role of interim Head of Finance in December.
"We are at an exciting stage of the Company's development, and
Grant's business experience in international commercial and
large-scale research and development organisations will assist the
Board and management team in delivering against our strategic
objectives."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763 7498
Shore Capital (Nomad and Broker)
Edward Mansfield/Anita Ghanekar/Daniel Bush Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations)
Simon Conway Tel: +44 20 3727 1000
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our biopharmaceutical
clients' neurological therapeutic pipelines through the application
of novel medical imaging and mobile health digital
technologies.
IXICO's data analytics services are used by the global
biopharmaceutical industry to interpret data from brain scans and
digital biosensors to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and
secure infrastructure for the capture and analysis of regulatory
compliant clinical data to enable clients to make rapid, better
informed decisions. IXICO is also collaborating with partners to
develop new analytical techniques and companion digital health
products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKMGGZVVVGLZM
(END) Dow Jones Newswires
February 07, 2019 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024